Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs2.47 B2.87 B3.89 B3.95 B2.97 B2.89 B2.92 BRecherche et développement521 M534 M605 M667 M590 M518 M517 MRésultat d'exploitation1.62 B1.71 B-1.94 B390 M14 M-308 M-300 MTotal des produits hors exploitation-272 M-45 M-56 M-30 M101 M81 M14 MCharges d'intérêts, nettes des intérêts capitalisés153 M206 M415 M512 M408 M290 M—Résultat hors exploitation, hors charges d'intérêts-235 M-210 M-456 M-491 M-345 M-250 M-95 MRevenus/dépenses exceptionnels-190 M-41 M-15 M-51 M38 M41 M32 MRésultat avant impôts1.29 B1.48 B-2.35 B-103 M-289 M-505 M-508 MPart des actionnaires dans le résultat———————Impôts182 M182 M68 M-34 M37 M395 M473 MIntérêts ne donnant pas le contrôle / intérêts minoritaires8 M11 M12 M7 M11 M00Autres produits/charges après impôts-86 M-92 M12 M-77 M-41 M-30 M-37 MRésultat net avant activités abandonnées1.1 B1.28 B-2.43 B-76 M-337 M-900 M-981 MActivités abandonnées0——2.73 B-312 M-57 M-117 MRésultat net1.1 B1.28 B-2.43 B2.66 B-649 M-957 M-1.1 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires1.1 B1.28 B-2.43 B2.66 B-649 M-957 M-1.1 BBénéfice par action de base (BPA de base)2.172.56-4.835.25-1.27-1.87-2.15Bénéfice par action dilué (BPA dilué)2.132.53-4.835.25-1.27-1.87-2.15Nombre moyen d'actions de base en circulation509 M502 M504 M506 M510 M513 M—Nombre d'actions en circulation après dilution517 M508 M504 M506 M510 M513 M—EBITDA1.67 B1.82 B-1.94 B-231 M-239 M-1 B-1.16 BEBIT488 M551 M-4.27 B-2.35 B-1.22 B-1.98 B-2.13 BCoût des ventes7.09 B7.68 B9.72 B9.84 B6.65 B7.87 B7.91 BAutres coûts des ventes———14 M9 M——Amortissements (flux de trésorerie)823 M890 M1.4 B1.26 B997 M981 M971 M
Baxter International Inc. Common Stock
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion, across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals.
Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients.
Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services".
Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology.